Literature DB >> 34023860

Upregulated PPARG2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer.

Feng Li1,2,3, Tingting Lu1,3, Dongmei Liu1,3, Chong Zhang3, Yonghui Zhang3, Fulu Dong4,5.   

Abstract

Prostate cancer (PCA) is one of the most common male genitourinary tumors. However, the molecular mechanisms involved in the occurrence and progression of PCA have not been fully clarified. The present study aimed to investigate the biological function and molecular mechanism of the nuclear receptor peroxisome proliferator-activated receptor gamma 2 (PPARG2) in PCA. Our results revealed that PPARG2 was downregulated in PCA, and overexpression of PPARG2 inhibited cell migration, colony formation, invasion and induced cell cycle arrest of PCA cells in vitro. In addition, PPARG2 overexpression modulated the activation of the Akt signaling pathway, as well as inhibited tumor growth in vivo. Moreover, mechanistic analysis revealed that PPARG2 overexpression induced increased expression level of miR-200b-3p, which targeted 3' UTR of the downstream targets DNMT3A/3B, and facilitated interaction with demethylated AKAP12 gene promoter and suppressed cell proliferation in PCA. Our findings provided the first evidence for a novel PPARG2-AKAP12 axis mediated epigenetic regulatory network. The study identified a molecular mechanism involving an epigenetic modification that could be possibly targeted as an antitumoral strategy against prostate cancer.

Entities:  

Year:  2021        PMID: 34023860     DOI: 10.1038/s41419-021-03820-7

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  39 in total

Review 1.  State-of-the-art approaches to detecting early bone metastasis in prostate cancer.

Authors:  Ramesh Thurairaja; Jon McFarlane; Zoe Traill; Rajendra Persad
Journal:  BJU Int       Date:  2004-08       Impact factor: 5.588

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 3.  Distinct but complementary contributions of PPAR isotypes to energy homeostasis.

Authors:  Vanessa Dubois; Jérôme Eeckhoute; Philippe Lefebvre; Bart Staels
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

4.  Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.

Authors:  Joshua A Roth; Roman Gulati; John L Gore; Matthew R Cooperberg; Ruth Etzioni
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

Review 5.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 6.  Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Joshua J Fenton; Meghan S Weyrich; Shauna Durbin; Yu Liu; Heejung Bang; Joy Melnikow
Journal:  JAMA       Date:  2018-05-08       Impact factor: 56.272

Review 7.  Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer.

Authors:  Ming Jiang; Scott B Shappell; Simon W Hayward
Journal:  J Cell Biochem       Date:  2004-02-15       Impact factor: 4.429

8.  Family history is significantly associated with prostate cancer and its early onset in Chinese population.

Authors:  Yang Xu; Da Huang; Yishuo Wu; Dingwei Ye; Ning Zhang; Yi Gao; Danfeng Xu; Rong Na; Jianfeng Xu
Journal:  Prostate       Date:  2019-09-09       Impact factor: 4.104

Review 9.  The Diagnosis and Treatment of Prostate Cancer: A Review.

Authors:  Mark S Litwin; Hung-Jui Tan
Journal:  JAMA       Date:  2017-06-27       Impact factor: 56.272

Review 10.  Rethinking prostate cancer screening: could MRI be an alternative screening test?

Authors:  David Eldred-Evans; Henry Tam; Heminder Sokhi; Anwar R Padhani; Mathias Winkler; Hashim U Ahmed
Journal:  Nat Rev Urol       Date:  2020-07-21       Impact factor: 14.432

View more
  2 in total

1.  AKAP12 ameliorates liver injury via targeting PI3K/AKT/PCSK6 pathway.

Authors:  Xuan Wu; Yuhong Luo; Shan Wang; Yueying Li; Meiyu Bao; Yuanjiang Shang; Lei Chen; Weiwei Liu
Journal:  Redox Biol       Date:  2022-05-06       Impact factor: 10.787

Review 2.  Regulatory functions of miR‑200b‑3p in tumor development (Review).

Authors:  Sheng Chen; Yifeng Tu; Hang Yuan; Zhan Shi; Yang Guo; Wenjing Gong; Shiliang Tu
Journal:  Oncol Rep       Date:  2022-03-24       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.